6 hours Ago By Defense World Staff
Cantor Fitzgerald restated their overweight rating on shares of ALX Oncology ( NASDAQ:ALXO – Free Report ) in a report published on Wednesday morning, Benzinga reports. Separately, HC Wainwright reaffirmed a “buy” rating and set a $25.00 price target on shares of ALX Oncology in a research note on Wednesday.
Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, ALX Oncology has a consensus rating of “Moderate Buy” and a consensus target price of $8.
50. View Our Latest Research Report on ALXO ALX Oncology Stock Up 9.5 % Insider Activity at ALX Oncology In related news, Director Rekha Hemrajani bought 30,000 shares of the firm’s stock in a transaction that occurred on Monday, December 2nd.
The shares were acquired at an average cost of $1.55 per share, with a total value of $46,500.00.
Following the completion of the transaction, the director now owns 33,000 shares of the company’s stock, valued at approximately $51,150. The trade was a 1,000.00 % increase in their ownership of the stock.
The transaction was disclosed in a document filed with the SEC, which is available at the SEC website . Insiders own 33.40% of the company’s stock.
Hedge Funds Weigh In On ALX Oncology A number of large investors have recently bought and sold shares of ALXO. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of ALX Oncology by 394.8% during the 2nd quarter.
Zurcher Kantonalbank Zurich Cantonalbank now owns 6,517 shares of the company’s stock valued at $39,000 after buying an additional 5,200 shares during the period. SG Americas Securities LLC boosted its holdings in ALX Oncology by 33.6% in the third quarter.
SG Americas Securities LLC now owns 27,394 shares of the company’s stock valued at $50,000 after acquiring an additional 6,888 shares during the last quarter. Hsbc Holdings PLC purchased a new stake in ALX Oncology during the second quarter valued at about $63,000. GSA Capital Partners LLP purchased a new stake in ALX Oncology during the third quarter valued at about $88,000.
Finally, Barclays PLC increased its stake in ALX Oncology by 243.6% during the third quarter. Barclays PLC now owns 59,502 shares of the company’s stock worth $107,000 after acquiring an additional 42,185 shares during the last quarter.
Hedge funds and other institutional investors own 97.97% of the company’s stock. ALX Oncology Company Profile ( Get Free Report ) ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States.
The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. Featured Stories Five stocks we like better than ALX Oncology How is Compound Interest Calculated? Opal Fuels CEO on Steering the Future of Renewable Natural Gas How to Buy Cheap Stocks Step by Step MicroStrategy Joins Nasdaq-100: 2 Crypto Stocks Set to Win Why Special Dividends Can be a Delightful Surprise for Income Investors 2 Underrated Quantum Computing Companies Starting to Rally Receive News & Ratings for ALX Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ALX Oncology and related companies with MarketBeat.com's FREE daily email newsletter .
.
